[US-헬스케어] 05/28 Wall St. Recap
LLYBULL Eli Lilly (LLY) continues to demonstrate robust momentum, underpinned by the explosive commercial success of its (obesity therapeutics), specifically Mounjaro and Zepbound. The company’s Q1 earnings report exceeded market expectations, validating its dominant position in the high-growth (GLP-1 receptor…